Scholar Rock's Weight-Loss Drug Preserves Muscle in Phase 2 Trial
TL;DR Summary
Scholar Rock's investigational drug apitegromab, when combined with Eli Lilly’s Zepbound, helped preserve lean muscle mass in patients undergoing weight loss, addressing concerns about muscle loss with obesity treatments.
- Scholar Rock says its drug preserved lean mass in patients taking Zepound statnews.com
- Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss Yahoo Finance
- Scholar Rock's SMA drug helps weight loss patients on Zepbound retain muscle in phase 2 trial Fierce Biotech
- Scholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial Results Investopedia
- Wall Street futures subdued ahead of Fed's interest rate verdict marketscreener.com
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 1 min read
Condensed
84%
187 → 29 words
Want the full story? Read the original article
Read on statnews.com